MaxCyte Inc
MXCT2.045USD
+0.005+0.25%
Market hours （ET）Quotes delayed by 15 min
217.41MMarket Cap
LossP/E TTM
More Details of MaxCyte Inc Company
MaxCyte, Inc. is a cell-engineering focused company providing solutions to advance the discovery, development and commercialization of cell therapeutics. It leverages its cell engineering technology platform to enable the programs of its biotechnology and pharmaceutical company customers who are engaged in cell therapy. Its ExPERT platform, which is based on its Flow Electroporation technology, is designed to support the expanding cell therapy market and can be utilized across the continuum of the cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes four instruments, the ATx, STx, GTx and VLx; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a worldwide intellectual property portfolio. It also provides comprehensive off-target risk assessment solutions for gene editing, through ONE-seq and GUIDE-seq platforms.
Company Info
Ticker SymbolMXCT
Company nameMaxCyte Inc
IPO dateMar 29, 2016
CEOMr. Maher Masoud, J.D.
Number of employees114
Security typeOrdinary Share
Fiscal year-endMar 29
Address9713 Key West Avenue,
CityROCKVILLE
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code20850
Phone13015175556
Websitehttps://www.maxcyte.com/
Ticker SymbolMXCT
IPO dateMar 29, 2016
CEOMr. Maher Masoud, J.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Stanley C. (Stan) Erck
Mr. Stanley C. (Stan) Erck
Non-Executive Independent Director
Non-Executive Independent Director
298.33K
+10.85%
Mr. John Joseph Johnston
Mr. John Joseph Johnston
Non-Executive Independent Director
Non-Executive Independent Director
171.16K
+20.58%
Dr. Richard H. Douglas, Ph.D.
Dr. Richard H. Douglas, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
150.58K
+24.07%
Ms. Rekha Hemrajani
Ms. Rekha Hemrajani
Non-Executive Independent Director
Non-Executive Independent Director
50.58K
+136.71%
Dr. Yasir B. Al-Wakeel
Dr. Yasir B. Al-Wakeel
Non-Executive Independent Director
Non-Executive Independent Director
50.58K
+136.71%
Mr. Douglas J. (Doug) Swirsky
Mr. Douglas J. (Doug) Swirsky
Chief Financial Officer
Chief Financial Officer
--
-100.00%
Ms. Cynthia L. Collins
Ms. Cynthia L. Collins
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Maher Masoud, J.D.
Mr. Maher Masoud, J.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. William W. (Will) Brooke, J.D.
Mr. William W. (Will) Brooke, J.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Ali Soleymannezhad
Mr. Ali Soleymannezhad
Chief Commercial Officer
Chief Commercial Officer
--
-100.00%
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Stanley C. (Stan) Erck
Mr. Stanley C. (Stan) Erck
Non-Executive Independent Director
Non-Executive Independent Director
298.33K
+10.85%
Mr. John Joseph Johnston
Mr. John Joseph Johnston
Non-Executive Independent Director
Non-Executive Independent Director
171.16K
+20.58%
Dr. Richard H. Douglas, Ph.D.
Dr. Richard H. Douglas, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
150.58K
+24.07%
Ms. Rekha Hemrajani
Ms. Rekha Hemrajani
Non-Executive Independent Director
Non-Executive Independent Director
50.58K
+136.71%
Dr. Yasir B. Al-Wakeel
Dr. Yasir B. Al-Wakeel
Non-Executive Independent Director
Non-Executive Independent Director
50.58K
+136.71%
Mr. Douglas J. (Doug) Swirsky
Mr. Douglas J. (Doug) Swirsky
Chief Financial Officer
Chief Financial Officer
--
-100.00%
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2025Q1
FY2024
By BusinessUSD
Name
Revenue
Proportion
Product sales
5.32M
51.16%
Licenses
4.68M
45.01%
other
397.00K
3.82%
By RegionUSD
Name
Revenue
Proportion
Inside the United States
8.03M
77.32%
Outside the United States
2.36M
22.68%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Product sales
5.32M
51.16%
Licenses
4.68M
45.01%
other
397.00K
3.82%
Shareholding Stats
Updated: Thu, Jul 24
Updated: Thu, Jul 24
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Cadian Capital Management LP
9.42%
BlackRock Institutional Trust Company, N.A.
6.97%
The Vanguard Group, Inc.
5.23%
Vitruvian Partners LLP
4.74%
Mirabella Financial Services LLP
3.48%
Other
70.16%
Shareholders
Shareholders
Proportion
Cadian Capital Management LP
9.42%
BlackRock Institutional Trust Company, N.A.
6.97%
The Vanguard Group, Inc.
5.23%
Vitruvian Partners LLP
4.74%
Mirabella Financial Services LLP
3.48%
Other
70.16%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
24.01%
Investment Advisor
23.62%
Hedge Fund
14.89%
Private Equity
4.83%
Research Firm
3.90%
Individual Investor
1.42%
Bank and Trust
0.71%
Pension Fund
0.16%
Insurance Company
0.03%
Other
26.41%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
294
78.23M
73.51%
-18.98M
2025Q1
308
82.56M
77.59%
-14.89M
2024Q4
308
80.42M
75.91%
-14.30M
2024Q3
300
80.65M
76.72%
-18.62M
2024Q2
297
80.25M
76.66%
-17.97M
2024Q1
302
79.09M
75.86%
-22.52M
2023Q4
303
79.97M
77.01%
-14.24M
2023Q3
292
77.05M
74.47%
-17.27M
2023Q2
284
79.82M
77.43%
-11.81M
2023Q1
275
80.19M
77.98%
-11.53M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Cadian Capital Management LP
10.03M
9.42%
+683.30K
+7.31%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
7.41M
6.97%
+63.83K
+0.87%
Mar 31, 2025
The Vanguard Group, Inc.
5.57M
5.23%
+135.98K
+2.50%
Mar 31, 2025
Vitruvian Partners LLP
5.04M
4.74%
--
--
Mar 31, 2025
Mirabella Financial Services LLP
3.70M
3.48%
--
--
Mar 31, 2025
Morgan Stanley Investment Management Inc. (US)
3.55M
3.34%
-547.43K
-13.36%
Mar 31, 2025
Morgan Stanley & Co. LLC
3.44M
3.23%
+3.16M
+1117.21%
Mar 31, 2025
Mudita Advisors LLP
3.33M
3.13%
+105.03K
+3.26%
Mar 31, 2025
River Global Investors LLP
3.25M
3.06%
+1.19M
+57.73%
Dec 31, 2024
Fidelity Management & Research Company LLC
2.75M
2.59%
-180.54K
-6.15%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
Invesco NASDAQ Future Gen 200 ETF
0.41%
iShares Micro-Cap ETF
0.05%
Invesco Nasdaq Biotechnology ETF
0.03%
ProShares Ultra Nasdaq Biotechnology
0.03%
Avantis US Small Cap Equity ETF
0.02%
iShares Russell 2000 Value ETF
0.02%
iShares Biotechnology ETF
0.02%
Proshares Ultra Russell 2000
0.01%
iShares Russell 2000 ETF
0.01%
Global X Russell 2000 ETF
0.01%
View more
Invesco NASDAQ Future Gen 200 ETF
Proportion0.41%
iShares Micro-Cap ETF
Proportion0.05%
Invesco Nasdaq Biotechnology ETF
Proportion0.03%
ProShares Ultra Nasdaq Biotechnology
Proportion0.03%
Avantis US Small Cap Equity ETF
Proportion0.02%
iShares Russell 2000 Value ETF
Proportion0.02%
iShares Biotechnology ETF
Proportion0.02%
Proshares Ultra Russell 2000
Proportion0.01%
iShares Russell 2000 ETF
Proportion0.01%
Global X Russell 2000 ETF
Proportion0.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
